CRISPR Therapeutics (CRSP) Announces $325M Common Share Offering
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/29/2026
Go back to CRISPR Therapeutics (CRSP) Announces $325M Common Share Offering
July 1, 2020 5:53 AM EDT
CRISPR Therapeutics (NASDAQ: CRSP), a biopharmaceutical company focused on developing transformative gene-based medicines for serious diseases, today announced the pricing of an underwritten public offering of 6,428,572 common shares at a public offering price of $70.00 per share. In addition, the underwriters have a 30-day... More
June 29, 2020 8:59 AM EDT
Piper Sandler analyst Edward Tenthoff reiterated an Overweight rating and $104.00 price target on CRISPR Therapeutics (NASDAQ: CRSP) citing a new manufacturing facility to produce cell therapies for clinical and commercial use, the hiring of up to 100 more full-time employees, Car-T advancing, and AACR II showing superior features of Allo Car-T Pipeline.
The... More
June 25, 2020 8:08 AM EDT
CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseases, today announced that it is building a new cell therapy manufacturing facility in Framingham, Massachusetts for clinical and commercial production of the Companys investigational cell therapy product... More
